Information
Address

Gustave Roussy
114, rue Édouard-Vaillant
94805 Villejuif Cedex - France
Switchboard:

Switchboard

+33 (0)1 42 11 42 11

GUSTAVE ROUSSY
1st cancer center in Europe

© 2006-2015 Gustave Roussy – All rights reserved

Cytometry & Mass imaging - Team members

back to job offer list
back to clinical trials

Cytometry & Mass imaging - Team members

Operational manager:
Philippe Rameau (Research Engineer)
Tel. 01.42.11.51.38
philippe.rameau@gustaveroussy.fr

Cyril Catelain (Research Engineer)
Tel. 01.42.11.51.38
cyril.catelain@gustaveroussy.fr

Cytometry & Mass imaging - Publications

back to job offer list
back to clinical trials

Cytometry & Mass imaging - Publications

  • Low Doses of Radiation Increase the Immunosuppressive Profile of Lung Macrophages During Viral Infection and Pneumonia Meziani L, Robert C, Classe M, Da Costa B, Mondini M, Clémenson C, Alfaro A, Mordant P, Ammari S, Le Goffic R, Deutsch E.. Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1283-1294. doi: 10.1016/j.ijrobp.2021.03.022. Epub 2021 Mar 13. PMID: 33722770; PMCID:PMC7954779.

    Cytometry & Mass imaging - Equipments

    back to job offer list
    back to clinical trials

    Cytometry & Mass imaging - Equipments

    Mass cytometer HELIOS (Fluidigm)

    As a complementary tool to flow cytometers, the mass cytometer considerably increases the number of parameters that can be analyzed (>40), while eliminating the problems of overlapping fluorescence spectrums observed with conventional cytometry.

    Cytometry and Mass imaging - Activities

    back to job offer list
    back to clinical trials

    Cytometry & Mass imaging - Activities

    Training and coaching

    • Flow, spectral and mass cytometry
    • Cell sorting and single-cell isolation
    • Mass imaging for molecular, cellular and functional spatial mapping of cells and tissues
    • Bioinformatics adapted to the unsupervised analysis of cytometry and imaging data.

    Design of experimental procedures

    Research in Immunotherapy

    back to job offer list
    back to clinical trials

    PREMIS: A programme dedicated to immunotherapy toxicity

    By stimulating patients' immune systems, immunotherapy drugs can generate autoimmune side effects, especially when used in combination, which can affect several organs, sometimes irreversibly. Yet there are no biomarkers to identify patients at risk of developing severe complications. Their discovery is a major objective in improving the management and safety of treated patients.

    Projet de recherche - Les cellules tumorales brouillent-elles les conversations des cellules immunitaires pour se protéger ?

    back to job offer list
    back to clinical trials

    Projet de recherche
    UMR 981 - Prédicteurs moléculaires et nouvelles cibles en oncologie

    Les cellules tumorales brouillent-elles les conversations des cellules immunitaires pour se protéger ?

    Projet de recherche de l’équipe du Dr Olivia Fromigué, soutenu par la fédération Enfants Cancers Santé (2022 - 2024)

    Prism

    back to job offer list
    back to clinical trials

    A flagship collaborative programme to virtualize cancer

    Logo Prism

    RHU REVEAL : l’intérêt de la biopsie liquide dans le cancer du poumon

    back to job offer list
    back to clinical trials

    Recherche hospitalo-universitaire

    RHU REVEAL : l’intérêt de la biopsie liquide dans le cancer du poumon

    Investir l'avenir

    The Data Science Programme

    back to job offer list
    back to clinical trials
    Cancer is a complex disease. It is vital to cross-reference the opinions of professionals in the various care and research disciplines (oncologists, biologists, geneticists, anatomopathologists and radiologists, etc.) in order to gain the most comprehensive overview and offer each patient the best therapeutic option or direct them towards an appropriate clinical trial. The aim of the "DATA SCIENCE" programme is to draw on a large volume of data relating to the diagnosis and management of previously treated patients to facilitate comparison.

    RHU Organomic : des organoïdes pour prédire la réponse aux traitements dans le cadre des cancers digestifs

    back to job offer list
    back to clinical trials

    Recherche hospitalo-universitaire

    RHU Organomic : des organoïdes pour prédire la réponse aux traitements dans le cadre des cancers digestifs

    Investir l'avenir

    Pages